
Jounce (JNCE) Stock: Gilead’s GS-1811 Buyout Allows A Further Bounce
iLexx/iStock via Getty Images Thesis Jounce Therapeutics (NASDAQ:JNCE) has been on my radar for quite a while, in light of its impressive pipeline, oversold-looking chart, and the Gilead deal on immunotherapy candidate GS-1181. That Gilead […]